Banking

Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Arcturus Therapeutics (ARCT) stock cleared that benchmark Wednesday, with a jump from 73 to 83 Wednesday.




X



When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock’s price performance over the last 52 weeks matches up against the rest of the market.

Over 100 years of market history reveals that the market’s biggest winners tend to have an 80 or better RS Rating as they launch their biggest runs.


See How IBD Helps You Make More Money In Stocks


Is Arcturus Therapeutics Stock A Buy?

Arcturus Therapeutics stock is working on a consolidation with a 65.10 buy point. See if the stock can break out in volume at least 40% higher than normal. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”

 

Earnings growth dropped in the company’s latest report from 0% to -276%, but revenue rose from -20% to -14%.

Arcturus Therapeutics stock holds the No. 291 rank among its peers in the Medical-Biomed/Biotech industry group. Alkermes (ALKS) and Innoviva (INVA) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”

YOU MIGHT ALSO LIKE:

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button